Audit: QRS - MDMA for Health & Longevity

Audit conducted on 21/07/2026 02:31 using AI4L / Opus 4.8

Summary

Items	Count
Total	91
Passed	81
Failed	0
N/A	10
Pass Rate	100.00%

Total = Passed + Failed + N/A
Pass Rate = Passed / (Passed + Failed) × 100
N/A items are excluded from the pass rate calculation

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values, gates, benefits, risks, and monitoring targets trace to the ER (dose 80–120 mg ER l.339; contraindications ER l.309; monitoring table ER l.405-412).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Speculative tiers and “promising but less settled” / “remain speculative” in At-A-Glance mirror the ER Conclusion (l.448).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications preserved as absolute (pregnancy/breastfeeding kept in stop gate, ER l.309).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates derive from ER “Key Interactions & Contraindications”; benefits/risks from their own ER sections; no cross-labeling.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, or expert names introduced in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Objective, data-aware tone consistent with the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Maintained across sections.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents evidence without prescribing.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No directive language; footer disclaimer present.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Content is presented, not recommended.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are contextual and minimal.
2.8	Information is presented in a concise and very compact manner	🟢	Condensed cells and bullets throughout.
2.9	It DOES NOT address the reader directly	🟢	No direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing matches the ER’s longevity-oriented audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol detail assumes an engaged reader.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Consistent with proactive audience.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Longevity framing preserved (e.g., stress-load/healthspan speculative benefit).
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	Title/header use “Longevity”; no “anti-aging”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology used (e.g., “oral”, “hyponatremia”); “talk therapy” is drawn from the ER’s own wording.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Table column headers in Monitoring (“Marker”, “Target”, “Why”).	🟢	All fixed headings and labels present and unmodified (QRS l.440,477,519,570,589,675; gates l.539,552; headers l.593-595).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All expected data-qrs-var spans present and populated.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	No unrelated spans altered.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped to a QRS field is empty; every populated field has ER content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Qualitative labels (Emotional regulation, Sleep quality, etc.) match ER bold labels (l.416-422).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names and qualitative labels verbatim from ER.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; tiers conveyed via bold labels and CSS.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content condensed into single-page card layout.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment opens at l.2, immediately after doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML delimited by “—” at l.3 and l.13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; not rendered.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; only “duration” quoted (contains colon).
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: mdma_2026-0721-0103_Opus_ER.md (l.4).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 (l.5), matches QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0721-0224 (l.6).
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus (l.7).
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 4.8 (l.8).
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 4.8” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: mdma_2026-0721-0103_Opus_QRS.html (l.9).
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Frontmatter clean and consistent.

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER `frontmatter` followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., `&` for `&`)	🟢	“MDMA for Health & Longevity - Quick Reference Sheet” (l.22).
6.2	[header_topic] is set to the [canonical_topic] of the ER `frontmatter`, with HTML entities encoded as needed (e.g., `&` for `&`)	🟢	“MDMA for Health & Longevity” (l.417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	07/21/2026 (l.421) from qrs_creation_date 2026-0721-0224.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 4.8” (l.425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Subline only states date, ER link, AI4L, and model.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER `Conclusion` section	🟢	Condenses the ER Conclusion (l.446-448).
7.2	[at_a_glance] is no longer than 60 words	🟢	52 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Fear reduction, trauma benefit, mood/relationship, speculative longevity, cardiovascular/emotional risk all in ER Conclusion.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Plain language (“talk therapy”, “emotional processing”); no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trials cited.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All stop items trace to ER l.293-309.
8.2	[stop_items] represent the Contraindications from the ER	🟢	MAOIs (absolute, l.293), serotonergic antidepressants same session (l.295), and the “Populations who should avoid” set (l.309) all captured.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six `<li>` items (l.542-547).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact.	🟢	No trailing dashes or rationale; only key facts.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(within 90 days)” and “(Child-Pugh Class C)” preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER contraindications use no ranking-notation parentheses.
8.7	If no [stop_items] are present the section is left empty	N/A	Stop items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All caution items trace to ER l.297-307.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Six cautions (CYP2D6 inhibitors, stimulants, dextromethorphan, supplements, lithium/tramadol, alcohol); MAOIs and SSRIs/SNRIs correctly excluded (in Contraindications).
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Six `<li>` items (l.555-560).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash — these trailing clauses are stripped. Just the key fact.	🟢	No mechanistic trailers; concise.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example-drug lists preserved (e.g., “fluoxetine, paroxetine, bupropion, ritonavir”).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets use no ranking-notation parentheses.
9.7	If no [caution_items] are present the section is left empty	N/A	Caution items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER `Protocol` section	🟢	Dose, course, session all from ER Therapeutic Protocol (l.335-339).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER `Protocol` section	🟢	Dose (80–120 mg), Course (2–3 monthly sessions), Session (6–8 h, two-therapist).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects present.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER `Protocol` section.	🟢	All labels/values/subs populated from ER.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Trauma symptom improvement, durability of benefit, acute onset.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered high-benefit trauma improvement first, then durability, then acute onset.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three aspects present.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“Weeks to months” (ER l.383), “Months to a year+” (l.367), “30–60 min” (l.383).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the `Protocol Panel`	N/A	The ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER `Expected Benefits` section	🟢	All tiers trace to ER l.141-195.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four present.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Benefit headings only, no magnitudes or mechanism.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content carried over.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER `Potential Risks & Side Effects` section	🟢	All tiers trace to ER l.217-273.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four present.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Risk headings only; “⚠️ Conflicted” markers and magnitudes stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	“(Hyponatremia)” and “(Hyperthermia)” stripped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER `Monitoring` section	🟢	Table mirrors ER Monitoring Protocol table (l.405-412).
14.2	All measurable/quantifiable biomarkers from the `Monitoring` section are listed	🟢	All six markers present (blood pressure, heart rate/rhythm, serum sodium, liver enzymes, eGFR, CAPS-5).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER `Monitoring` section. It is not left with placeholder text or empty.	🟢	Cadence populated from ER l.403 (l.669).

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER `Monitoring` section	🟢	Drawn from ER qualitative markers (l.416-422).
15.2	All subjective/qualitative biomarkers from the `Monitoring` section are listed	🟢	Emotional regulation, sleep quality, relationships and engagement, mood and outlook — all four present.

Issues 21/07/2026 02:31

Pass rate 100.00%. No issues found.